FDA Approves Expanded Indication for Merck's CAPVAXIVE® Pneumococcal Vaccine in At-Risk Children and Adolescents

The U.S. Food and Drug Administration (FDA) has approved an additional indication for Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for children and adolescents aged 2 through 17 years who are at increased risk for pneumococcal disease. CAPVAXIVE is the only Pneumococcal Conjugate Vaccine specifically indicated and studied in the U.S. for this population, providing additional protection by including serotypes not found in existing primary pediatric vaccination series.